Last reviewed · How we verify
OLE FD Adalimumab +/- MTX
Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling to reduce inflammation, with optional methotrexate co-administration to enhance efficacy.
Adalimumab (Humira) is a fully human monoclonal antibody TNF-α inhibitor developed by Abbott for inflammatory and autoimmune diseases. This profile focuses on the pediatric polyarticular juvenile idiopathic arthritis (pJIA) formulation studied in Phase 3 trials, with or without methotrexate co-therapy. Adalimumab binds TNF-α with high affinity, blocking its interaction with TNF receptors and suppressing the inflammatory cascade central to JIA pathogenesis. The compound has achieved FDA approval across multiple adult and pediatric indications including rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis, generating peak annual revenues exceeding $16B globally. Clinical differentiation in pediatric JIA derives from demonstrated efficacy in reducing active joint counts and improving functional outcomes, with favorable safety profiles when combined with conventional DMARDs. Abbott's biosimilar competition and patent cliff (US composition patents expired 2023) have driven recent revenue decline, though the pediatric indication and newer formulations (pen/pre-filled syringe) maintain market relevance.
At a glance
| Generic name | OLE FD Adalimumab +/- MTX |
|---|---|
| Also known as | ABT-D2E7, Humira |
| Sponsor | Abbott |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha (Tumor Necrosis Factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Adalimumab is a fully human monoclonal antibody that binds to and neutralizes TNF-alpha, a key pro-inflammatory cytokine. By blocking TNF-alpha, it suppresses the inflammatory cascade underlying autoimmune diseases. The addition of methotrexate (MTX) provides synergistic immunosuppression and is commonly used in combination therapy for rheumatoid arthritis and other inflammatory conditions.
Approved indications
- Rheumatoid arthritis (with or without methotrexate)
- Polyarticular juvenile idiopathic arthritis
- Ankylosing spondylitis
- Crohn's disease
- Ulcerative colitis
- Psoriasis
- Psoriatic arthritis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Tuberculosis reactivation
- Serious infections
- Malignancy risk
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OLE FD Adalimumab +/- MTX CI brief — competitive landscape report
- OLE FD Adalimumab +/- MTX updates RSS · CI watch RSS
- Abbott portfolio CI